AR062911A1 - Uso de los moduladores de lxrs para la prevencion y tratamiento del envejecimiento de la piel - Google Patents

Uso de los moduladores de lxrs para la prevencion y tratamiento del envejecimiento de la piel

Info

Publication number
AR062911A1
AR062911A1 ARP070104148A ARP070104148A AR062911A1 AR 062911 A1 AR062911 A1 AR 062911A1 AR P070104148 A ARP070104148 A AR P070104148A AR P070104148 A ARP070104148 A AR P070104148A AR 062911 A1 AR062911 A1 AR 062911A1
Authority
AR
Argentina
Prior art keywords
expression
induces
lxr
inhibits
treatment
Prior art date
Application number
ARP070104148A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR062911A1 publication Critical patent/AR062911A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Birds (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Reivindicacion 1: Una composicion antienvejecimiento de la piel que comprende una cantidad terapéuticamente efectiva de un modulador LXR. Reivindicacion 13: Un método para el tratamiento del envejecimiento cutáneo que comprende la administracion a un mamífero que lo necesita de una cantidad terapéuticamente efectiva de un modulador de LXR. Reivindicacion 22: Un método para identificar un modulador de LXR capaz de inducir un efecto antienvejecimiento de la piel que comprende: (a) proporcionar una muestra que contiene LXR; (b) poner en contacto la muestra con un compuesto de ensayo; y (c) determinar si el compuesto de ensayo induce la expresion de TIMP1, induce la expresion de ASAH1, induce la expresion de SPTLC1, induce la expresion de SMPD1 induce la expresion de LASS2, induce la expresion de TXNRD1, induce la expresion de GPX3, induce la expresion de GSR, induce la expresion de CAT, induce la expresion de ABCA1, induce la expresion de ABCA2, induce la expresion de ABCA12, induce la expresion de ABCA13, induce la expresion de ABCG1, induce la expresion de decorina, inhibe la expresion TNFalfa, inhibe la expresion MMP1, inhibe la expresion MMP3, inhibe la expresion IL-8 o una de sus combinaciones mediante un mecanismo basado en LXR. Reivindicacion 23: El uso de un modulador de LXR en la fabricacion de un medicamento para el tratamiento o prevencion del envejecimiento de la piel.
ARP070104148A 2006-09-19 2007-09-19 Uso de los moduladores de lxrs para la prevencion y tratamiento del envejecimiento de la piel AR062911A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84568506P 2006-09-19 2006-09-19

Publications (1)

Publication Number Publication Date
AR062911A1 true AR062911A1 (es) 2008-12-17

Family

ID=39110878

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104148A AR062911A1 (es) 2006-09-19 2007-09-19 Uso de los moduladores de lxrs para la prevencion y tratamiento del envejecimiento de la piel

Country Status (5)

Country Link
US (1) US20080070883A1 (es)
AR (1) AR062911A1 (es)
PE (1) PE20080844A1 (es)
TW (1) TW200819145A (es)
WO (1) WO2008036238A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9532994B2 (en) 2003-08-29 2017-01-03 The Regents Of The University Of California Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
US9670244B2 (en) * 2006-02-27 2017-06-06 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
US20100048944A1 (en) * 2006-07-19 2010-02-25 Farhad Parhami Interactions of hedgehog and liver x receptor signaling pathways
WO2008082520A2 (en) * 2006-12-19 2008-07-10 The Regents Of The University Of California Inhibition of ppar gamma expression by specific osteogenic oxysterols
EP2146724A2 (en) * 2007-03-16 2010-01-27 The Regent of the University of California Role of hedgehog signaling in atherosclerosis and cardiovascular disease
BRPI0811091A8 (pt) * 2007-05-18 2015-09-29 Wyeth Corp Composto, composição farmacêutica, métodos para prevenir ou tratar uma doença, distúrbio ou condição, para aumentar níveis de colesterol hdl no soro em um indivíduo, para reduzir níveis de colestetol ldl no soro em um indivíduo, para aumentar o transporte invertido de colesterol em um indivíduo, e para reduzir a absorção do colesterol em um indivíduo, e, uso de um composto
CA2698928A1 (en) * 2007-09-28 2009-04-09 Absolute Science, Inc. Compounds and methods for treating zinc matrix metalloprotease dependent diseases
EP2231164A1 (en) * 2007-12-03 2010-09-29 The Regents of the University of California Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling
CN101945871A (zh) * 2007-12-21 2011-01-12 惠氏有限责任公司 咪唑并[1，2-a]吡啶化合物
CN101952257A (zh) * 2007-12-21 2011-01-19 惠氏有限责任公司 苯并咪唑化合物
BRPI0822239A2 (pt) * 2007-12-21 2015-06-30 Wyeth Llc Composto de pirazolo[1,5-a] pirimidina
WO2009086130A1 (en) * 2007-12-21 2009-07-09 Wyeth Imidazo [1,2-b] pyridazine compounds as modulators of liver x receptors
CA2724322C (en) 2008-05-14 2019-07-16 Dermtech International Diagnosis of melanoma and solar lentigo by nucleic acid analysis
CA2737437A1 (en) * 2008-09-19 2010-03-25 Absolute Science, Inc. Methods of treating a botulinum toxin related condition in a subject
EP2349348A4 (en) * 2008-11-03 2013-06-26 Dermachip Inc COMPOSITIONS AND METHOD FOR REDUCING SIGNS FOR SKIN AGING
US20100120778A1 (en) * 2008-11-07 2010-05-13 Wyeth Quinoxaline-based lxr modulators
CA2742023A1 (en) * 2008-11-19 2010-05-27 Wyeth Llc Polar quinazolines as liver x receptors ( lxrs ) modulators
WO2011006087A1 (en) * 2009-07-10 2011-01-13 The Regents Of The University Of California Inhibition of ppar gamma expression in preadipocyte cells by oxysterols
KR101766393B1 (ko) * 2010-11-30 2017-08-10 (주)아모레퍼시픽 블레오마이신 하이드로라제를 이용한 건조 피부 개선물질 스크리닝 방법
EP2710373B1 (en) * 2011-05-17 2015-06-17 Chanel Parfums Beauté Screening of large activators for preventing and/or attenuating skin ageing and/or hydrating skin
IN2014MN01065A (es) 2011-12-06 2015-05-01 Unilever Plc
JP6262723B2 (ja) 2012-05-07 2018-01-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ オキシステロールアナログｏｘｙ１３３は、骨発生及びヘッジホッグシグナル伝達を誘導し、脂肪生成を阻害する
CA2911205A1 (en) 2013-05-02 2014-11-06 The Regents Of The University Of California Bone-selective osteogenic oxysterol-bone targeting agents
CN105132358B (zh) * 2015-07-29 2019-12-06 苏州诺普再生医学有限公司 培养获得组织工程表皮的方法及其应用
WO2017115319A2 (en) * 2015-12-30 2017-07-06 Consejo Nacional De Investigaciones Científicas Y Técnicas (Conicet) Use of brassinosteroid analogs for the treatment of dermal disorders by selectively modulating liver x receptors (lxr) and dermal disease treatment by brassinosteroid analogs acting as selective liver x receptor (lxr) modulators
EP3752645A4 (en) 2018-02-14 2022-04-13 Dermtech, Inc. NEW GENE CLASSIFIERS AND THEIR USES IN NON-MELANOMA SKIN CANCERS
US11578373B2 (en) 2019-03-26 2023-02-14 Dermtech, Inc. Gene classifiers and uses thereof in skin cancers
CA3136108A1 (en) * 2019-04-05 2020-10-08 Dermtech, Inc. Novel gene classifiers for use in monitoring uv damage

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60120805A (ja) * 1983-11-30 1985-06-28 Akira Kitano 皮膚化粧料
US5492894A (en) * 1991-03-21 1996-02-20 The Procter & Gamble Company Compositions for treating wrinkles comprising a peptide
US6060515A (en) * 1997-01-24 2000-05-09 The Regents Of The University Of California Treatment of skin conditions by use of PPARα activators
US6316503B1 (en) * 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
US20030086923A1 (en) * 1999-12-13 2003-05-08 Sparrow Carl P. Method for the prevention and/or treatment of atherosclerosis
US20020010128A1 (en) * 2000-04-13 2002-01-24 Parks Thomas P. Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism
WO2003030857A1 (en) * 2001-10-04 2003-04-17 Unilever Plc Enhancing epidermal barrier development in skin
BR0215258A (pt) * 2001-12-21 2004-12-07 Pharmacia Corp Moduladores de receptor x de fìgado de tioéter aromático
US7482366B2 (en) * 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
AU2002351412B2 (en) * 2001-12-21 2010-05-20 Exelixis Patent Company Llc Modulators of LXR
US20050123580A1 (en) * 2002-02-28 2005-06-09 Burris Thomas P. Method of treating atherosclerosis and hypercholesterolemia
MXPA04011691A (es) * 2002-05-24 2005-09-12 Pharmacia Corp Moduladores del receptor x anilino hepaticos.
JP3694494B2 (ja) * 2002-07-02 2005-09-14 三井金属鉱業株式会社 車両スライド扉の動力装置
US20040110947A1 (en) * 2002-09-17 2004-06-10 Pharmacia Corporation Aromatic liver X-receptor modulators
WO2004058175A2 (en) * 2002-12-23 2004-07-15 Irm Llc Novel use of liver x receptor agonists
US20040259948A1 (en) * 2003-01-10 2004-12-23 Peter Tontonoz Reciprocal regulation of inflammation and lipid metabolism by liver X receptors
WO2004064769A2 (en) * 2003-01-21 2004-08-05 Hector Herrera Methods for making and using topical delivery agents
EP1620419A4 (en) * 2003-04-21 2008-07-23 Tagra Biotechnologies Ltd STABILIZED DERIVATIVES OF ASCORBIC ACID
US20050009837A1 (en) * 2003-05-20 2005-01-13 City Of Hope Modulators of lipid metabolism and methods of use
KR20070001922A (ko) * 2003-12-12 2007-01-04 와이어쓰 심장혈관질환 치료에 유용한 퀴놀린
CN101213194A (zh) * 2004-08-03 2008-07-02 惠氏公司 可用于治疗心血管疾病的吲唑化合物
CN101087754B (zh) * 2004-12-22 2012-01-18 霍夫曼-拉罗奇有限公司 环己烷衍生物
AU2006218661A1 (en) * 2005-03-01 2006-09-08 Wyeth Cinnoline compounds and their use as liver X receptor modilators

Also Published As

Publication number Publication date
US20080070883A1 (en) 2008-03-20
TW200819145A (en) 2008-05-01
WO2008036238A3 (en) 2011-08-11
WO2008036238A2 (en) 2008-03-27
PE20080844A1 (es) 2008-08-15

Similar Documents

Publication Publication Date Title
AR062911A1 (es) Uso de los moduladores de lxrs para la prevencion y tratamiento del envejecimiento de la piel
CL2010000720A1 (es) Método para la evaluar la respuesta a la inhibición de her en una muestra de paciente, que comprende detectar la proteina marcadora egf (div.sol.no. 1240-06).
BRPI0906478B8 (pt) anticorpo anti-nr10, seu uso e composição farmacêutica que o compreende
CR10237A (es) Anticuerpos contra la il-22 humana y usos para los mismos
BRPI0607472A2 (pt) fio de transponder bem como seu emprego
ATE509570T1 (de) Analytisches hilfsmittel mit lanzette und testelement
CL2011000207A1 (es) Composicion biocida que comprende ciprodinil y flutianil; metodo para controlar enfermedades en plantas utiles o en material de propagacion causadas por fitopatogenos (div. sol. n°2602-06).
DOP2009000140A (es) Anticuerpos humanos contra el ligando 4 de tipo delta humano
CR20110066A (es) Anticuerpos monoclonales contra el factor tisular inhibidor de la via
BRPI0912923A2 (pt) composto que consiste de um oligonucleotídeo modificadpo composto de 12-30 nucleosídeos ligados, compostos que compreende um oligonucleotídeo modificado que compreende pelo menos 12 nucleosídeos ligados, composto que compreende um oligonucleotídeo modificado que compreende nucleosídeos ligados, e, uso de um composto
CL2008001656A1 (es) Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene.
HN2008001104A (es) Compuestos para anticuerpos de dickpf-1 y70-4
CL2007003793A1 (es) Metodo para inhibir union del receptor de muerte 6 (dr6) a la proteina precursora amiloide (app) que comprende uno o mas antagonistas del dr6; uso de dichos antagonistas; metodo para identificar una molecula de interes que inhibe la union del dr6 a l
CL2008001879A1 (es) Compuestos derivados de isaxolinas-naftalen-carboamida; y el uso de los compuestos en el control de plagas de invertebrados en animales.
ES2572372T3 (es) Método de diagnóstico de enfermedades neurodegenerativas basado en la medición de los niveles o de la actividad de SIRT1
CL2008001741A1 (es) Anticuerpo quimerico o humanizado o fragmento de los mismos que se unen especificamente a por lo menos un epitope en la proteina beta-amiloide; molecula de acido nucleico que lo codifica; composicion que lo comprende; y su uso para tratar enfermedades asociados con la formacion de placas amiloides.
CL2007003807A1 (es) Anticuerpos humanos anti-cd44 o fragmentos de los mismos; acidos nucleicos que los codifican; vector y celula huesped que los comprende; composicion farmaceutica que comprende a los anticuerpos; y su uso para tratar los sintomas de trastornos mediado
CL2008000910A1 (es) Proteina de fusion que comprende una proteina que corta el peptido beta amiloide; composicion farmaceutica que la comprende, y su uso para prevenir y/o tratar enfermedades relacionadas con el peptido beta amiloide.
AR083259A1 (es) Cuantificacion y caracterizacion de los alergenos
BRPI0516149A (pt) instrumento de medição da elasticidade de um órgão do tipo que envolve um meio de centralização
BR112012002429A2 (pt) polipeptídeos de porphyromonas gingivalis
DE602008006407D1 (de) Verstärkter stabilisationsstreifen zur verwendung in verstärkten fundamenten
CL2022002944A1 (es) Anticuerpos de unión a vista a ph ácido (solicitud divisional de 202100012)
UY29417A1 (es) Agentes endoparasiticidas
BRPI0704496A (pt) pigmentos de óxido férrico estáveis à oxidação, processo para a fabricação de pigmentos de óxido férrico, uso dos pigmentos de óxido férrico

Legal Events

Date Code Title Description
FB Suspension of granting procedure